Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 8/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939645 | 0.92 | PDGFRB (0.53) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1941496 | 0.90 | NTRK1 (0.53) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1940703 | 0.90 | EIF2AK3 (0.53) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1941396 | 0.88 | NTRK1 (0.54) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1942841 | 0.87 | EIF2AK3 (0.53) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1941598 | 0.87 | NTRK1 (0.52) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1941754 | 0.87 | EIF2AK3 (0.51) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1940016 | 0.86 | EIF2AK3 (0.54) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1940938 | 0.86 | NTRK1 (0.52) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1939906 | 0.85 | PDGFRB (0.55) | EIF2AK3NTRK1NTRK2NTRK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | claimed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | claimed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | claimed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | EIF2AK3 2841/4885NTRK1 4135/4885NTRK2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.